Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX-LNP
- Development stage
- Preclinical
- Lead developer
- InhaTarget Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
VAX-LNP is an inhaled lipid nanoparticle (LNP)-based vaccine candidate under development by InhaTarget Therapeutics. It is designed to target antigen-presenting cells, specifically macrophages, in the lung to enhance immune priming and elicit a robust localized immune response. The candidate is being investigated at the research stage for the prevention of infectious lung diseases, including influenza (flu) and COVID-19, as well as for animal health indications.
Beyond the preview
Go deeper on VAX-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX-LNP.